Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Last verified 25 Sep 2026 · Editorial standards

At a glance

Lenalidomide is named as an intervention in 92 current clinical trials in our China, USA, UK, Ireland and India registers. 40 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Janssen Research & Development, LLC (8). The most-studied condition is Multiple Myeloma.

Lenalidomide also has an approved-drug profile on this site (FDA label data): Revlimid (Lenalidomide) →

Trials by status

Recruiting4043%
Not yet open1112%
Active, closed4043%
By invitation11%

Trials by phase

Phase 33538%
Phase 22426%
Phase 1/21617%
Phase 1910%
Phase 433%
Phase 2/322%
Phase EARLY_PHASE111%
Observational11%
Not applicable11%

Clinical trials of Lenalidomide

92 trials

Study	Phase	Status	Lead sponsor	Registers
Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma NCT06209606 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase EARLY_PHASE1	Recruiting	Oncotherapeutics	USA
Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma NCT05722405 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 4	Recruiting	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection NCT06409702 · ClinicalTrials.gov ↗ · Newly Diagnosed, High Risk, MRD	Phase 4	Recruiting	The First Affiliated Hospital of Soochow University	China
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation NCT05243797 · Multiple Myeloma	Phase 3	Recruiting	European Myeloma Network B.V.	Ireland, China
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma NCT05552222 · Multiple Myeloma	Phase 3	Recruiting	Janssen Research & Development, LLC	UK, USA, China
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant NCT05623020 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 3	Recruiting	Pfizer	UK, USA, China
Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma NCT06082102 · ClinicalTrials.gov ↗ · Relapsed/Refractory Marginal Zone Lymphoma	Phase 3	Recruiting	Beijing InnoCare Pharma Tech Co., Ltd.	China
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma NCT06084936 · ClinicalTrials.gov ↗ · Lymphoma	Phase 3	Recruiting	Hoffmann-La Roche	UK, USA, China
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma NCT06149286 · ClinicalTrials.gov ↗ · Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)	Phase 3	Recruiting	Regeneron Pharmaceuticals	UK, USA
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM) NCT06679101 · Multiple Myeloma, Newly Diagnosed Multiple Myeloma	Phase 3	Recruiting	GlaxoSmithKline	Ireland, UK, USA, India, China
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4) NCT06911502 · ClinicalTrials.gov ↗ · Follicular Lymphoma	Phase 3	Recruiting	Celgene	UK, USA, India, China
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant NCT06932562 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 3	Recruiting	European Myeloma Network B.V.	Ireland
A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant NCT07297329 · ClinicalTrials.gov ↗ · Multiple Myeloma (MM)	Phase 3	Recruiting	Sinocelltech Ltd.	China
A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma NCT07562022 · Follicular Lymphoma (FL)	Phase 3	Recruiting	Sinocelltech Ltd.	China
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT NCT07764978 · ClinicalTrials.gov ↗ · Newly Diagnosed Multiple Myeloma	Phase 3	Recruiting	AstraZeneca	UK, USA
A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related Disease NCT07068165 · ClinicalTrials.gov ↗ · IgG4 Related Disease	Phase 2/3	Recruiting	Peking Union Medical College Hospital	China
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant NCT07095452 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 2/3	Recruiting	AbbVie	USA
Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphoma NCT04737889 · ClinicalTrials.gov ↗ · Primary Central Nervous System Lymphoma	Phase 2	Recruiting	Henan Cancer Hospital	China
Chemotherapy Combined With Radiotherapy Versus Radiotherapy Alone for Solitary Plasmacytoma NCT05248633 · ClinicalTrials.gov ↗ · Solitary Plasmacytoma	Phase 2	Recruiting	Peking Union Medical College Hospital	China
Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma NCT06140966 · ClinicalTrials.gov ↗ · Multiple Myeloma, Primary Plasma Cell Leukemia, Extramedullary Multiple Myeloma	Phase 2	Recruiting	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	China
Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL NCT06151080 · ClinicalTrials.gov ↗ · DLBCL - Diffuse Large B Cell Lymphoma, Follicular Lymphoma	Phase 2	Recruiting	The First Affiliated Hospital of Xiamen University	China
Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL NCT06803693 · ClinicalTrials.gov ↗ · Diffuse Large B-Cell Lymphoma	Phase 2	Recruiting	Ruijin Hospital	China
Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma NCT07018050 · ClinicalTrials.gov ↗ · Relapsed or Refractory Multiple Myeloma	Phase 2	Recruiting	Qilu Pharmaceutical Co., Ltd.	China
A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma NCT07189065 · ClinicalTrials.gov ↗ · Diffuse Large B-Cell Lymphoma (DLBCL)	Phase 2	Recruiting	Guangzhou Lupeng Pharmaceutical Company LTD.	China
Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL NCT07208981 · ClinicalTrials.gov ↗ · Marginal Zone Lymphoma(MZL)	Phase 2	Recruiting	The First Affiliated Hospital with Nanjing Medical University	China
Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma NCT07261163 · ClinicalTrials.gov ↗ · Mantle Cell Lymphoma	Phase 2	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL NCT07448324 · ClinicalTrials.gov ↗ · Marginal Zone Lymphoma(MZL)	Phase 2	Recruiting	The First Affiliated Hospital with Nanjing Medical University	China
CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia NCT07652905 · ClinicalTrials.gov ↗ · Plasma Cell Leukemia (PCL)	Phase 2	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
Selinexor and Backbone Treatments of Multiple Myeloma Patients NCT02343042 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 1/2	Recruiting	Karyopharm Therapeutics Inc	USA
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies NCT04068597 · Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma	Phase 1/2	Recruiting	CellCentric Ltd.	UK, USA
MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL) NCT04110301 · ClinicalTrials.gov ↗ · Follicular Lymphoma and Marginal Zone Lymphoma	Phase 1/2	Recruiting	Beijing Mabworks Biotech Co., Ltd.	China
Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement NCT04432714 · ClinicalTrials.gov ↗ · DLBCL, Untreated, MYC Gene Rearrangement	Phase 1/2	Recruiting	The First Affiliated Hospital with Nanjing Medical University	China
A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma NCT04669171 · ClinicalTrials.gov ↗ · Follicular Lymphoma, Marginal Zone Lymphoma	Phase 1/2	Recruiting	Enterome	USA
Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM) NCT06087653 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 1/2	Recruiting	Starton Therapeutics, Inc	USA
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations NCT06892522 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 1/2	Recruiting	AbbVie	UK, USA
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients NCT03110822 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 1	Recruiting	Oncotherapeutics	USA
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments NCT05137054 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 1	Recruiting	Regeneron Pharmaceuticals	USA
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma NCT06768489 · ClinicalTrials.gov ↗ · Multiple Myeloma, Smoldering Multiple Myeloma, Immunoglobulin Light-chain Amyloidosis	Phase 1	Recruiting	Janssen Research & Development, LLC	USA
Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients NCT07663253 · ClinicalTrials.gov ↗ · Multiple Myeloma	Observational	Recruiting	Shanghai Zhongshan Hospital	China
Risk Stratification and MRD-driven Maintenance for MM After ASCT NCT06697483 · ClinicalTrials.gov ↗ · Multiple Myeloma	Not applicable	Recruiting	Peking University People's Hospital	China
A Single-center, Prospective, Single-arm Clinical Study Exploring the Treatment of Newly Diagnosed Multiple Myeloma Patients With t(11;14) Suitable for Transplantation Using the SonKRd Regimen NCT07709884 · ClinicalTrials.gov ↗ · Newly Diagnosed Multiple Myeloma, T(11;14), Sotoclax	Phase 4	Not yet open	The First Affiliated Hospital of Soochow University	China
IMM0306 in Combination With Lenalidomide vs Placebo in Combination With Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma NCT07355283 · ClinicalTrials.gov ↗ · Relapsed/Refractory Follicular Lymphoma	Phase 3	Not yet open	ImmuneOnco Biopharmaceuticals (Shanghai) Inc.	China
Efficacy and Safety of Lenalidomide in Patients With IgG4-Related Disease NCT07719543 · ClinicalTrials.gov ↗ · Immunoglobulin G4-Related Disease	Phase 3	Not yet open	Chinese PLA General Hospital	China
A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular Lymphoma NCT07719855 · ClinicalTrials.gov ↗ · Follicular Lymphoma ( FL)	Phase 3	Not yet open	Ruijin Hospital	China
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6). NCT07735637 · ClinicalTrials.gov ↗ · Newly Diagnosed Multiple Myeloma (NDMM)	Phase 3	Not yet open	AstraZeneca	UK, USA
A Clinical Trial to Evaluate the Efficacy and Safety of TQB3909 Tablets Versus Investigator's Choice in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) NCT07753369 · ClinicalTrials.gov ↗ · Small Lymphocytic Lymppho, Relapsed/Refractory Chronic Lymphocytic Leukemia	Phase 3	Not yet open	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	China
A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide NCT07585747 · ClinicalTrials.gov ↗ · Follicular Lymphoma	Phase 2	Not yet open	Institute of Hematology & Blood Diseases Hospital, China	China
AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL NCT07594899 · ClinicalTrials.gov ↗ · Large B-Cell Lymphoma (LBCL)	Phase 2	Not yet open	Ruijin Hospital	China
AI-Driven Treatment Strategy vs ZR2 in Older Treatment-naive Patients With LBCL NCT07717177 · ClinicalTrials.gov ↗ · Large B-Cell Lymphoma (LBCL)	Phase 2	Not yet open	Ruijin Hospital	China
A Open-Label Phase in Participants With Multiple Myeloma NCT07764861 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 2	Not yet open	Innovent Biologics (Suzhou) Co. Ltd.	China
CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple Myeloma NCT07830485 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 2	Not yet open	Institute of Hematology & Blood Diseases Hospital, China	China
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab NCT05669989 · ClinicalTrials.gov ↗ · Plasma Cell Myeloma	Phase 2	By invitation	Sanofi	USA, China
Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma NCT01169337 · ClinicalTrials.gov ↗ · Light Chain Deposition Disease, Smoldering Multiple Myeloma	Phase 3	Active, closed	National Cancer Institute (NCI)	Ireland
A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant NCT03319667 · ClinicalTrials.gov ↗ · Plasma Cell Myeloma	Phase 3	Active, closed	Sanofi	USA, China
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma NCT04270409 · ClinicalTrials.gov ↗ · Plasma Cell Myeloma	Phase 3	Active, closed	Sanofi	Ireland, UK, USA, China
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL NCT04404283 · ClinicalTrials.gov ↗ · Diffuse Large B-cell Lymphoma	Phase 3	Active, closed	Seagen, a wholly owned subsidiary of Pfizer	UK, USA
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. NCT04680052 · ClinicalTrials.gov ↗ · Follicular Lymphoma, Marginal Zone Lymphoma	Phase 3	Active, closed	Incyte Corporation	Ireland, UK, USA, China
A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma NCT04712097 · Relapsed or Refractory Follicular Lymphoma	Phase 3	Active, closed	Hoffmann-La Roche	UK, USA, China
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients NCT04824092 · ClinicalTrials.gov ↗ · Diffuse Large B-cell Lymphoma	Phase 3	Active, closed	Incyte Corporation	Ireland, UK, USA
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy NCT04923893 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 3	Active, closed	Janssen Research & Development, LLC	Ireland, UK, USA
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma NCT05100862 · Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma	Phase 3	Active, closed	BeOne Medicines	Ireland, UK, USA, China
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant NCT05317416 · Multiple Myeloma	Phase 3	Active, closed	Pfizer	UK, USA, India, China
Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma NCT05371093 · ClinicalTrials.gov ↗ · Relapsed/Refractory Follicular Lymphoma	Phase 3	Active, closed	Kite, A Gilead Company	UK, USA
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma NCT05409066 · ClinicalTrials.gov ↗ · Follicular Lymphoma (FL)	Phase 3	Active, closed	Genmab	UK, USA, China
Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND) NCT05429268 · ClinicalTrials.gov ↗ · Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma	Phase 3	Active, closed	Incyte Corporation	Ireland, UK
A Study of Daratumumab NCT05438043 · Multiple Myeloma	Phase 3	Active, closed	Janssen Research & Development, LLC	UK, USA, China
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma NCT05827016 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 3	Active, closed	Bristol-Myers Squibb	UK, USA, India, China
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation NCT06045806 · Multiple Myeloma	Phase 3	Active, closed	Celgene	UK, USA
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma NCT06191744 · ClinicalTrials.gov ↗ · Follicular Lymphoma (FL)	Phase 3	Active, closed	Genmab	UK, USA, China
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma NCT06508658 · ClinicalTrials.gov ↗ · Diffuse Large B-Cell Lymphoma	Phase 3	Active, closed	Genmab	UK, USA, China
Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma NCT01415752 · ClinicalTrials.gov ↗ · Lymphoma, Mantle Cell Lymphoma	Phase 2	Active, closed	Eastern Cooperative Oncology Group	Ireland
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma NCT04133636 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 2	Active, closed	Janssen Research & Development, LLC	USA
Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma NCT04782687 · ClinicalTrials.gov ↗ · Multiple Myeloma, Myeloma Multiple, Kahler Disease	Phase 2	Active, closed	US Oncology Research	USA
Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma NCT05123131 · Multiple Myeloma	Phase 2	Active, closed	Cancer Trials Ireland	Ireland
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma NCT05283720 · Non-Hodgkin Lymphoma	Phase 2	Active, closed	Genmab	USA, China
A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma NCT06577025 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 2	Active, closed	Janssen Research & Development, LLC	USA
JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma NCT07081022 · ClinicalTrials.gov ↗ · B-cell Non-Hodgkin's Lymphoma	Phase 2	Active, closed	Shanghai Junshi Bioscience Co., Ltd.	China
Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma NCT02180711 · ClinicalTrials.gov ↗ · Non Hodgkin Lymphoma	Phase 1/2	Active, closed	Acerta Pharma BV	USA
Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) NCT04126200 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 1/2	Active, closed	GlaxoSmithKline	USA
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma NCT04246086 · Follicular Lymphoma	Phase 1/2	Active, closed	Hoffmann-La Roche	UK, USA, China
Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome NCT04623541 · ClinicalTrials.gov ↗ · Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome	Phase 1/2	Active, closed	Genmab	USA
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) NCT04663347 · ClinicalTrials.gov ↗ · Diffuse Large B-Cell Lymphoma, Follicular Lymphoma	Phase 1/2	Active, closed	Genmab	UK, USA
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma NCT05201248 · ClinicalTrials.gov ↗ · B-Cell Non-Hodgkin Lymphoma	Phase 1/2	Active, closed	Genmab	China
Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients NCT05222555 · ClinicalTrials.gov ↗ · Diffuse Large B Cell Lymphoma	Phase 1/2	Active, closed	Incyte Corporation	USA
A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma NCT05950165 · ClinicalTrials.gov ↗ · Non-Hodgkin Lymphoma	Phase 1/2	Active, closed	Cho Pharma Inc.	China
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM NCT07150091 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 1/2	Active, closed	GlaxoSmithKline	USA
Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma NCT04091126 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 1	Active, closed	GlaxoSmithKline	UK, USA
A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma NCT04722146 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 1	Active, closed	Janssen Research & Development, LLC	UK, USA
A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma NCT05050097 · Multiple Myeloma	Phase 1	Active, closed	Janssen Research & Development, LLC	UK, USA
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma NCT05259839 · Relapsed/Refractory Multiple Myeloma	Phase 1	Active, closed	AbbVie	USA
A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets NCT05308654 · ClinicalTrials.gov ↗ · Relapsed/Refractory Multiple Myeloma	Phase 1	Active, closed	AbbVie	UK, USA
Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) NCT06547944 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Newly Diagnosed	Phase 1	Active, closed	Institute of Hematology & Blood Diseases Hospital, China	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Conditions studied with Lenalidomide

60 conditions

Multiple Myeloma35Follicular Lymphoma7Relapsed/Refractory Follicular Lymphoma4Diffuse Large B-Cell Lymphoma4Marginal Zone Lymphoma3Newly Diagnosed Multiple Myeloma3Plasma Cell Myeloma3Follicular Lymphoma (FL)3Lymphoma2Mantle Cell Lymphoma2Diffuse Large B-cell Lymphoma2Smoldering Multiple Myeloma2

All 60 conditions

Condition (as registered)	Trials
Multiple Myeloma	35
Follicular Lymphoma	7
Relapsed/Refractory Follicular Lymphoma	4
Diffuse Large B-Cell Lymphoma	4
Marginal Zone Lymphoma	3
Newly Diagnosed Multiple Myeloma	3
Plasma Cell Myeloma	3
Follicular Lymphoma (FL)	3
Lymphoma	2
Mantle Cell Lymphoma	2
Diffuse Large B-cell Lymphoma	2
Smoldering Multiple Myeloma	2
Non Hodgkin Lymphoma	2
Relapsed/Refractory Multiple Myeloma	2
Non-Hodgkin Lymphoma	2
Relapsed/Refractory Chronic Lymphocytic Leukemia	2
Small Lymphocytic Lymphoma	2
Newly Diagnosed	2
Large B-Cell Lymphoma (LBCL)	2
Marginal Zone Lymphoma(MZL)	2
Large B-Cell Lymphoma	1
Light Chain Deposition Disease	1
Haematological Malignancy	1
Acute Myeloid Leukemia	1
Relapsed or Refractory Follicular Lymphoma	1
Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)	1
Newly Diagnosed Multiple Myeloma (NDMM)	1
Immunoglobulin Light-chain Amyloidosis	1
Diffuse Large B Cell Lymphoma	1
Myeloma Multiple	1
Kahler Disease	1
Myeloma, Plasma Cell	1
Richter's Syndrome	1
Treatment-naïve High Risk Chronic Lymphocytic Leukemia	1
B-Cell Non-Hodgkin Lymphoma	1
Follicular Lymphoma ( FL)	1
Chronic Lymphocytic Leukemia	1
Primary Plasma Cell Leukemia	1
Extramedullary Multiple Myeloma	1
Small Lymphocytic Lymppho	1
Follicular Lymphoma and Marginal Zone Lymphoma	1
DLBCL - Diffuse Large B Cell Lymphoma	1
B-cell Non-Hodgkin's Lymphoma	1
DLBCL	1
Untreated	1
MYC Gene Rearrangement	1
High Risk	1
MRD	1
Relapsed/Refractory Marginal Zone Lymphoma	1
Multiple Myeloma (MM)	1
T(11;14)	1
Sotoclax	1
Carfilzomib	1
Plasma Cell Leukemia (PCL)	1
IgG4 Related Disease	1
Diffuse Large B-Cell Lymphoma (DLBCL)	1
Solitary Plasmacytoma	1
Relapsed or Refractory Multiple Myeloma	1
Immunoglobulin G4-Related Disease	1
Primary Central Nervous System Lymphoma	1

By country register

Register	Trials	Recruiting
Clinical trials in China	55	27
Clinical trials in USA	51	17
Clinical trials in UK	32	9
Clinical trials in Ireland	12	3
Clinical trials in India	4	2

A trial with sites in more than one country appears in each of those registers.

Related compounds

Questions about Lenalidomide trials

How many clinical trials are testing Lenalidomide?

92 current trials in our China, USA, UK, Ireland and India registers name Lenalidomide as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.

Are Lenalidomide trials recruiting patients?

Yes. 40 of the 92 trials are recruiting: 27 with sites in China, 17 with sites in USA, 9 with sites in UK, 3 with sites in Ireland and 2 with sites in India. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Lenalidomide clinical trials?

Janssen Research & Development, LLC (8), Genmab (7), Institute of Hematology & Blood Diseases Hospital, China (5) and GlaxoSmithKline (4), among 48 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Lenalidomide works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Lenalidomide works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Lenalidomide (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Lenalidomide clinical trials